Hennion & Walsh Asset Management, Inc. Replimune Group, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$17.48 - $29.09 $20,434 - $34,006	-1,169 Reduced 3.31%	34,131 $603,000
Q4 2022 Jan 12, 2023	BUY	$17.09 - $27.91 $76,255 - $124,534	4,462 Added 14.47%	35,300 $960,000
Q3 2022 Nov 14, 2022	SELL	$15.6 - $21.15 $6,661 - $9,031	-427 Reduced 1.37%	30,838 $533,000
Q2 2022 Jul 19, 2022	SELL	$13.32 - $19.98 $6,180 - $9,270	-464 Reduced 1.46%	31,265 $547,000
Q1 2022 Apr 26, 2022	BUY	$15.24 - $29.75 $9,845 - $19,218	646 Added 2.08%	31,729 $539,000
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $49,435 - $66,582	1,944 Added 6.67%	31,083 $842,000
Q3 2021 Nov 12, 2021	BUY	$28.98 - $39.54 $289,133 - $394,490	9,977 Added 52.07%	29,139 $864,000
Q2 2021 Aug 13, 2021	BUY	$28.5 - $39.37 $546,117 - $754,407	19,162 New	19,162 $736,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $694M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.